JP2020504604A5 - - Google Patents

Download PDF

Info

Publication number
JP2020504604A5
JP2020504604A5 JP2019533144A JP2019533144A JP2020504604A5 JP 2020504604 A5 JP2020504604 A5 JP 2020504604A5 JP 2019533144 A JP2019533144 A JP 2019533144A JP 2019533144 A JP2019533144 A JP 2019533144A JP 2020504604 A5 JP2020504604 A5 JP 2020504604A5
Authority
JP
Japan
Prior art keywords
tnfα
trimmer
compound
binding
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019533144A
Other languages
English (en)
Japanese (ja)
Other versions
JP7198755B2 (ja
JP2020504604A (ja
Filing date
Publication date
Priority claimed from GBGB1621907.3A external-priority patent/GB201621907D0/en
Application filed filed Critical
Publication of JP2020504604A publication Critical patent/JP2020504604A/ja
Publication of JP2020504604A5 publication Critical patent/JP2020504604A5/ja
Priority to JP2022150888A priority Critical patent/JP2022184988A/ja
Application granted granted Critical
Publication of JP7198755B2 publication Critical patent/JP7198755B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019533144A 2016-12-21 2017-12-13 抗体エピトープ Active JP7198755B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022150888A JP2022184988A (ja) 2016-12-21 2022-09-22 抗体エピトープ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1621907.3 2016-12-21
GBGB1621907.3A GB201621907D0 (en) 2016-12-21 2016-12-21 Antibody epitope
PCT/EP2017/082685 WO2018114538A1 (en) 2016-12-21 2017-12-13 Antibody epitope

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022150888A Division JP2022184988A (ja) 2016-12-21 2022-09-22 抗体エピトープ

Publications (3)

Publication Number Publication Date
JP2020504604A JP2020504604A (ja) 2020-02-13
JP2020504604A5 true JP2020504604A5 (https=) 2021-01-28
JP7198755B2 JP7198755B2 (ja) 2023-01-04

Family

ID=58284667

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019533144A Active JP7198755B2 (ja) 2016-12-21 2017-12-13 抗体エピトープ
JP2022150888A Withdrawn JP2022184988A (ja) 2016-12-21 2022-09-22 抗体エピトープ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022150888A Withdrawn JP2022184988A (ja) 2016-12-21 2022-09-22 抗体エピトープ

Country Status (7)

Country Link
US (3) US11174311B2 (https=)
EP (1) EP3559031A1 (https=)
JP (2) JP7198755B2 (https=)
CN (1) CN110291106A (https=)
CA (1) CA3047193A1 (https=)
GB (1) GB201621907D0 (https=)
WO (1) WO2018114538A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2647427B2 (ja) 1987-04-24 1997-08-27 帝人株式会社 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット
US4908372A (en) 1988-10-13 1990-03-13 Merrell Dow Pharmaceuticals Inc. Antihistaminic piperidinyl benzimidazoles
DE3843534A1 (de) 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US6451983B2 (en) 1989-08-07 2002-09-17 Peptech Limited Tumor necrosis factor antibodies
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
IT1249708B (it) 1991-09-23 1995-03-09 Tecnogen Scpa Metodo per la determinazione del fattore di necrosi tumorale (tnf) in forma biologicamente attiva.
TW231291B (https=) 1992-01-09 1994-10-01 Janssen Pharmaceutica Nv
US5891679A (en) 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
CA2119089A1 (en) 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
DE4440613C1 (de) 1994-11-14 1996-07-25 Leica Ag Vorrichtung und Verfahren zur Detektion und Demodulation eines intensitätsmodulierten Strahlungsfeldes
TW453995B (en) 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
NZ524980A (en) 2000-09-01 2005-10-28 Biogen Idec Inc Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications
EP1414810B1 (en) 2001-06-05 2006-08-30 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzo-fused cycloalkyl urea compounds
US6632810B2 (en) 2001-06-29 2003-10-14 Kowa Co., Ltd. Cyclic diamine compound with condensed-ring groups
JP2003040888A (ja) 2001-07-30 2003-02-13 Sankyo Co Ltd イミダゾール誘導体
US20060078944A1 (en) 2002-08-01 2006-04-13 Jun Kuai Methods and reagents relating to inflammation and apoptosis
CA2524623A1 (en) 2003-05-09 2004-11-18 Pharmexa A/S Immunogenic human tnf alpha analogues with reduced cytotoxicity and methods of their preparation
AR045056A1 (es) * 2003-07-15 2005-10-12 Amgen Inc Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf
US7268116B2 (en) 2003-10-02 2007-09-11 Genhunter Corp. Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins
TW200526780A (en) 2004-01-06 2005-08-16 Hayashibara Biochem Lab TNF antagonists and TNF inhibitors comprising the same as the active ingredient
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
KR20170036814A (ko) 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
TW201531484A (zh) 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc 抗ＴＮＦ-α之抗體及其用途
TW200914052A (en) 2007-08-03 2009-04-01 Alcon Res Ltd RNAi-related inhibition of TNFα signaling pathway for treatment of glaucoma
US9365644B2 (en) 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
KR102050040B1 (ko) 2008-06-25 2019-11-28 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
AU2009318779A1 (en) 2008-11-20 2011-07-07 Panacea Biotec Ltd Tumor Necrosis Factor alpha inhibiting peptides and uses thereof
JP2010172307A (ja) 2009-01-30 2010-08-12 Saitama Medical Univ 関節リウマチに対する可溶性ＴＮＦα／ＬＴαレセプター薬の薬効予測方法、及び薬効予測装置
WO2010118404A2 (en) 2009-04-09 2010-10-14 California Institute Of Technology Methods for creating or identifying compounds that bind tumor necrosis factor alpha
PE20120835A1 (es) 2009-04-16 2012-07-23 Abbvie Biotherapeutics Inc Anticuerpos anti-tnf-alfa y sus usos
KR20130010123A (ko) 2010-04-07 2013-01-25 아비에 인코포레이티드 ＴＮＦ-α 결합 단백질
US8377441B2 (en) 2010-08-03 2013-02-19 National Cheng Kung University Treating breast cancer with anti-IL-19 antibody
EP2632448B1 (en) 2010-10-30 2020-10-21 KinDex Pharmaceuticals, Inc. Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(-3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods
AR084210A1 (es) * 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
WO2012172070A1 (en) 2011-06-17 2012-12-20 Glaxo Group Limited Tumour necrosis factor receptor 1 antagonists
WO2013024040A2 (en) 2011-08-12 2013-02-21 B.S.R.C. Alexander Fleming Tnf superfamily trimerization inhibitors
BR112014030940B1 (pt) 2012-06-11 2022-09-06 UCB Biopharma SRL Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos
EP2867674B1 (en) 2012-06-28 2018-10-10 UCB Biopharma SPRL A method for identifying compounds of therapeutic interest
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
CN104619709B (zh) 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
EP3738605A1 (en) 2012-09-10 2020-11-18 Xencor, Inc. Methods of treating neurological diseases
JP6134392B2 (ja) 2013-01-25 2017-05-24 サイモン・エルエルシー 循環している生物学的に活性な可溶性ｔｎｆの選択的低減用の組成物およびｔｎｆ媒介性疾患を処置する方法
US10173207B2 (en) 2013-03-12 2019-01-08 Anellotech, Inc. Regeneration of catalytic fast pyrolysis catalyst
US9908944B2 (en) 2013-07-15 2018-03-06 Novo Nordisk A/S Antibodies that bind urokinase plasminogen activator
GB201321740D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321734D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321731D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
ES2750236T3 (es) 2013-12-09 2020-03-25 UCB Biopharma SRL Derivados heteroaromáticos bicíclicos condensados como moduladores de la actividad del TNF
GB201321749D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321733D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321748D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
BR112016012243A2 (pt) 2013-12-09 2017-08-08 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de atividade de tnf
GB201321732D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321736D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
PE20170693A1 (es) 2014-10-03 2017-06-13 Ucb Biopharma Sprl Derivados de imidazol pentaciclicos fusionados
TWI703156B (zh) 2015-01-30 2020-09-01 學校法人埼玉醫科大學 抗ａｌｋ２抗體
AU2016233288A1 (en) 2015-03-18 2017-11-09 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
CA2982446A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds useful as inhibitors of tnf
MX2017011577A (es) 2015-03-18 2017-10-26 Bristol Myers Squibb Co Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf).
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
US20160304496A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
GB201509885D0 (en) 2015-06-08 2015-07-22 Ucb Biopharma Sprl Therapeutic agents
GB201509888D0 (en) 2015-06-08 2015-07-22 Ucb Biopharma Sprl Therapeutic agents
GB201509893D0 (en) 2015-06-08 2015-07-22 Ucb Biopharma Sprl Therapeutic agents
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
KR102679517B1 (ko) 2015-08-03 2024-06-27 브리스톨-마이어스 스큅 컴퍼니 Tnf 알파의 조정제로서 유용한 시클릭 화합물
EA033686B1 (ru) 2015-08-03 2019-11-15 Bristol Myers Squibb Co Гетероциклические соединения, применимые в качестве модуляторов tnf-альфа
EA201892144A1 (ru) 2016-04-01 2019-04-30 Юсб Байофарма Спрл Конденсированные гексациклические производные имидазола в качестве модуляторов активности tnf
EP3436460B1 (en) 2016-04-01 2021-08-18 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of tnf activity
JP6968091B2 (ja) 2016-04-01 2021-11-17 ユーシービー バイオファルマ エスアールエル Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
JP6968092B2 (ja) 2016-04-01 2021-11-17 ユーシービー バイオファルマ エスアールエル Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体

Similar Documents

Publication Publication Date Title
JP2018525333A5 (https=)
JP2018520668A5 (https=)
Christensen et al. Several distinct properties of the IgE repertoire determine effector cell degranulation in response to allergen challenge
EP2425259B1 (en) Immunoassay for the detection of procalcitonin
JP6055764B2 (ja) 乳癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
CN101405405A (zh) 预测对治疗的应答的方法
FI3356827T3 (fi) GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi
KR20130091746A (ko) 췌장암의 치료를 위한 베바시주맙 병용 치료법을 위한 혈장 생체마커
JP2023527937A5 (https=)
JP2011501946A5 (https=)
CN107076749A (zh) 转移性结直肠癌抗血管发生治疗相关预测和预后生物标志
JP2017524362A5 (https=)
JP2019504014A5 (https=)
JP2019504013A5 (https=)
WO2018165186A1 (en) Assessment of chronic iron deficiency
JP2020504604A5 (https=)
JP2018520127A5 (https=)
O'Shannessy et al. Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer
EP3746477A1 (en) Compounds that modulate the interaction of vista and vsig3 and methods of making and using
JP2021528411A5 (https=)
WO2014039605A2 (en) Chimeric anti-dsdna/chromatin antibody
CN115104029A (zh) 用于检测和监测全身性炎症的非侵入性测定法
CN121219584A (zh) 针对nr1的自身抗体的检测
JP7150618B2 (ja) 免疫グロブリン単一可変ドメインについての改善された薬物動態アッセイ
TW201915016A (zh) 單株抗體或其抗原結合片段及其用途